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ABSTRACT

Kerns, Scott Albert. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2009.
Effects of Direct Mechanical Ventricular Actuation on the Apoptotic Signaling of a
Failing Heart.

Cardiovascular disease accounts for more than 40% of all deaths in the United
States (AHA-2004 report). A non blood contacting ventricular assist device (VAD) can
be used to treat heart failure without the complications that arise from blood contacting
VADs. This study used cellular markers of heart failure as indicators of heart function in
an attempt to assess if direct mechanical ventricular actuation (DMVA) support lessened
the impact of heart failure in rabbits. Cell signaling proteins were monitored using
enzyme activity measurements and quantitative immunoblotting with antibodies against
intrinsic and extrinsic apoptotic pathways during heart failure with and without DMVA
support.
New Zealand White rabbits were treated as sham or heart failure, with or without
DMVA assistance. Animals had heart failure induced by esmolol, with or without
DMVA support for 30, 60, or 120 minutes. At all time points, animals were recovered
for 30 minutes after which the hearts were excised. Tissue extracts were prepared and
measurements were made using the following groups; acute model with sham and 30
iii

minute groups or an extended support/failure model with 60 minute and 120 minute
groups. Cell extracts from left and right ventricles were used for immunoblot analysis to
determine protein levels for the following heart failure markers; the extrinsic apoptotic
pathway comprised of tumor necrosis factor receptor (TNFR) and caspase-8, the intrinsic
apoptotic pathway comprised of caspase-9, cytochrome-C, or the stress related marker
of heat shock protein-70 (Hsp70). Enzymatic activity was used to monitor the extrinsic
pathway with caspase-8, or markers of stress with superoxide dismutase (SOD), and
matrix metalloproteinase-9 (MMP-9) in all heart extracts.
In the left ventricle acute model there was a rise in both 30 minute groups
compared to the sham group for all the markers, except in the caspase-8 enzymatic assay
where both groups showed less activity. The extended support/failure model showed that
the use of DMVA during heart failure significantly attenuated the increase of protein
content for TNFR, Hsp70, and caspase-8 at the 120 minute time point. The caspase-8
enzymatic assay showed a significant decrease in 120 minute DMVA assisted group
compared to the heart failure group. For every marker in the extended support/failure
model there was an increase in all the markers as the duration of the experiment
increased.
The right ventricle acute model exhibited an increase in both 30 minute groups for
TNFR content. A significant rise in SOD levels for the 30 minute heart failure compared
to both the sham and 30 DMVA groups. MMP-9 levels for both 30 minute groups rose
iv

significantly. In the extended support/failure model, the right ventricle showed a
significant increase of both groups at 120 minutes when compared to the 60 minute heart
failure group in TNFR and Hsp70 protein content. In the caspase-8 enzyme assay the
120 minute DMVA group had a significant rise when compared to the 60 minute heart
failure group.
DMVA provided evidence of the ability to attenuate the increase of pro-apoptotic
signaling during heart failure. Evidence of this was mostly observed in the left ventricle
samples, often significantly different. Both ventricles exhibited trends of attenuation by
DMVA in many markers that did not differ significantly. It should also be noted that at
no time point did DMVA appear to have a negative effect on the heart during failure.
The validity of the heart failure model being used was also confirmed by the continuing
increase in activation of known markers over time.
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I. Introduction
Overview of Ventricular Assist Devices
Cardiovascular disease accounted for 36.3% of all deaths in the United States in
2004, more than any other major cause of death. (Rosamond, 2007). The necessity for a
method of supporting the failing heart has been and still is an ever-growing concern. One
such method is the use of left ventricular assist-devices (LVADs) to provide circulatory
support during heart failure by unloading the heart (Miller, 2007). Current methods for
supporting a failing heart, which include LVADs and right ventricular assist devices
(RVADs), are broken into two groups based on their purpose. One group is for long term
support of over one month. These devices are large and expensive units, but are very
reliable for improving systemic blood-flow. Short term devices are used in cases where
patients are expected to recover or require suscitating support to evaluate prognosis or
consider further therapies (Catena, 2007). The fundamental configuration of an LVAD
includes an inflow cannula which diverts blood entering the LV into a prosthetic ventricle
that pumps the blood back into systemic circulation by means of an outflow cannula
positioned in the aorta. In general RVADs normally pump blood received by the right
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ventricle into pulmonary circulation via the pulmonary artery (Rose, 2001). The benefits
of this type of device relate to its ability to restore hemodynamics toward normal. This
can result in improved survival compared to relatively futile efforts of medical
management. An investigation of nontransplant-eligible patients was done in 2007
comparing optimal medical therapy to using LVAD support. The results showed that
using LVAD support significantly improved the survival rates after 6 months (46% vs.
22%; p = 0.03) and 12 months (27% vs. 11%; p = 0.02). Another positive aspect seen in
this study was that 85% of the patients that received LVAD support also showed minimal
to no heart failure symptoms. Despite these benefits, adverse effects associated with
VAD support remain problematic. These often stem from embolic events due to
thrombus formation on blood contacting surfaces despite the use of anticoagulants.
Anticoagulants used to prevent thrombo-embolic events are associated with an increased
risk for bleeding complications which require re-operation in up to 50% of patients. Often
these side effects that increase the mortality rates of LVAD supported patients (Rogers,
2007). Other studies have shown that infection can become a problematic side effect
from the LVAD which can lead to fatal sepsis was common. However, it is felt that these
adverse effects were outweighed by the LVADs ability to improve mortality rates
compared to medical therapy at one year (52% vs. 25%) and at two years (23% vs. 8%).
In this older study, the cause of death in LVAD supported patients was mainly due to
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sepsis and device failure, both of which are continually improved on aspects of the
device, as seen in the Rogers study described earlier (Rose, 2001).

Direct Mechanical Ventricular Actuation
A direct mechanical ventricular actuation device (DMVA) differs significantly
from the typical VAD. DMVA is non-blood contacting and provides biventricular
support. It is placed directly over the heart and pumps the ventricular chambers. Unlike
conventional LVADs that unload the heart, DMVA augments ventricular pump function
of the loaded heart. The DMVA (Fig. 1) is a cup shaped device that encompasses the
ventricle portion of the heart. This design allows it to be applied to both ventricles
without incisions in the heart or contact with the circulating blood. From the cup there
are two lines that connect it to a drive system. One line is at the apex of the heart and is a
vacuum that assures the device stays in place on the heart. The other line is connected to
a pulse pressure system that inflates and deflates a flexible membrane to simulate systolic
and diastolic forces. The device actively engages the ventricles and augments ventricular
function, somewhat like the use of open heart massage (Anstadt, 2002). Unlike heart
massage, DMVA is further unique in its ability to provide diastolic support. DMVA does
not require blood contact, and blood contact often leads to complications due to
coagulation of the blood. Therefore, DMVA does not require anticoagulation drugs,
which reduces the risk of bleeding complication. Because VADs pump blood through
3

Figure 2
Diagram of the direct mechanical ventricular actuation cup (DMVA). The DMVA
is a non-blood contacting ventricular assist device.

4

5

prosthetic ventricles, anticoagulants are required to prevent the blood from coagulating.
Blood contacting devices are associated with an increase for the risk of thrombo-embolic
events, hemorrhage, and infection (Lowe, 1991).Other problems with conventional
VADs relate to cannulation techniques and the blood’s flow to and from the VAD
system. For example, tissue can collapse over the inlet of the inflow cannula. This can
occur in a variety of places such as the interventricular septum, the left ventricular free
wall, or the mitral valve leaflets leading to inadequate VAD filling and low flow states
(Reesink, 2007). The DMVA system does not draw or push the circulating blood by
means of a vacuum, thus those complications do not appear to arise.

Esmolol Induced Acute Heart Failure
In this study heart failure was induced by using a short acting beta-blocker,
esmolol, to reduce contractility of the heart and lower cardiac output. Esmolol was an
appropriate candidate for this due to its moderate selectivity to beta-1 receptors, which
are predominately found in the heart. The other positive characteristic of esmolol is its
short half-life when compared to other beta-blockers. Esmolol has a half-life of 9
minutes, compared to 6-9 hours with Atenolol and 2.5-4.5 hours with Metoprolol, both
also have moderate selectivity to beta-1 receptors. The effects of esmolol are also
relatively quick, in 2 minutes effects can be seen and peak at around 5 minutes. Esmolol
is a drug commonly used for treating arrhythmias and hypertension (Frakes, 2001).
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Esmolol has had limited use as an acute heart failure model, but a 1997 study did show
its potential to induce arrest for a period of 120 minutes while still allowing for
satisfactory recovery within 35 minutes after infusion was stopped. Esmolol induces
heart failure by inhibition of catecholamine binding to beta-adrenergic receptors in the
cell membrane, which results in the decrease in heart rate and contractility. Heart failure
can thereby be modeled without direct injury to the myocardium. The metabolites from
esmolol are extremely weak acting and essentially do not exert any further effects on
other functions in the body. Toxic levels of esmolol infusion have been reported to cause
severe bradycardia and hypotension (Ede, 1997). Another study had shown esmolol to be
useful in inducing minimal myocardial contraction. This study did however conclude
that in cases longer than 2 hours the metabolites from esmolol could accumulate and
cause less favorable fluid filtration out of the myocardial capillaries. Esmolol was chosen
due to its ability to avoid the induction of ischemia, myocardial edema formation, and
post bypass cardiac function (Warters, 1998).

Ventricular Remodeling
As a result of heart failure, a process known as ventricular remodeling can occur
in the heart. Ventricular remodeling is related to local and systemic compensatory
responses that initially allow surviving muscle to compensate and maintain better
hemodynamics. Eventually the muscle initially unaffected becomes dysfunctional
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because of continued compensatory responses, termed maladaptive cell signaling (Friehs,
2006) (Drakos, 2007). These affects also can be seen at a cellular level, known as
myocardial remodeling. At this level the cardiomyocytes are undergoing alterations in
the contractile apparatus, cell size (hypertrophy), cell shape, and cell survival (Fedak,
2005). Although once thought to be an irreversible process, it has been shown that with
proper recovery of cardiac function with the use of devices such as LVADs, the process
of remodeling can be reversed by a process aptly named reverse remodeling. Reverse
remodeling, the reversal of cardiac remodeling to a point where patients no longer require
mechanical support, has been shown to be possible when a device or method is able to
decrease LV end diastolic volume, increase LV wall thickness and ejection fraction, and
improve hemodynamic function (Wohlschlaeger, 2005), (Drakos, 2007). The main
focus this study will examine how DMVA affects maladaptive cell signaling in the
acutely failing heart.

Overview of Apoptosis
Apoptosis is programmed cell death which is in response to cell injury and is
defined by the removal of the damaged cell while trying to preserve surrounding cells.
The affected cells in apoptosis are phagocytosed, preventing the release of intracellular
material and its accompanying inflammatory response (Scarabelli, 2006). Apoptosis is
viewed as the principal form of cellular death associated with heart failure (Cook, 1999).
8

Figure 2
The Intrinsic Pathway of Apoptosis. Initiated by intracellular signals, the intrinsic
pathway is a result from the interaction between Bcl-2 proteins and the
mitochondria. The mitochondria then release different factors, such as cytochrome
c, SMAC/DIABLO, and Omi/HtrA2 to form the apoptosome. The apoptosome then
activates caspase-9 starting the caspase cascade and apoptosis.
Adapted from Jin, 2005.
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For the cellular detection of apoptosis it is necessary to first focus on the initial markers
of the apoptotic pathway. There are two main groups known as the intrinsic and the
extrinsic pathways. The intrinsic pathway (Fig. 2) comes from an intracellular signals;
oxidative stress, DNA damage, and protein misfolding. Those signals cause a family of
Bcl-2 proteins to interact with the mitochondria. The interactions create the opening of
the mitochondrial permeability transition pore or can rupture the outer mitochondrial
membrane. Once the membrane is ruptured the mitochondria then release different
factors, such as cytochrome c, second mitochondria-derived activator of caspase/direct
IAP-binding protein with low pI (SMAC/DIABLO), and high temperature requirement
protein A2 (Omi/HtrA2) (Crow, 2004). Those factors initiate the formation of an
apoptosome, which in turn activates caspase-9 and finally caspase-3 resulting in cell
death (Riedl, 2007).

The Extrinsic Pathway of Apoptosis
The extrinsic pathway (Fig. 3) is initiated by extracellular signals and stress on the
cell. The main signaling for apoptosis in the heart occurs by two death receptors, the
tumor necrosis factor receptor 1 (TNFR1) and the Fas receptor (FasR). There are
corresponding ligands; the CD95 ligand (CD95L), TNF, and TNF-related apoptosisinducing ligand (TRAIL), which bind to the receptors (Scarabelli, 2006). Once the
appropriate ligands bind to a receptor death domain proteins are recruited; TNFR11

Figure 3
The Extrinsic Pathway of Apoptosis. Also known as the death receptor
pathway, it is characterized by the presence of death receptors. Ligands bind to
the corresponding receptor, which recruit death domains and eventually form a

12

13

associated death domain (TRADD) and the Fas-associated death domain (FADD). It is at
this time point that the caspase pathway is initiated. Those complexes recruit procaspase-8 to form the death-inducing signaling complex (DISC). The formation of the
DISC allows for the activation of pro-caspase-8 to caspase-8 by self-cleaving. The
caspases recruited early in apoptosis are called initiators; the initiators will act on other
downstream caspases known as effectors. In cardiac apoptosis there are two main
initiators (caspase-8 and caspase-9) along with one effector (caspase-3) (Jin, 2005).

Heat Shock Protein 70 and Its Relationship to Heart Failure
Another response found in a failing heart is the increase in heat shock protein 70
(Hsp70) activation. The purpose of Hsp70 is to reactivate denatured enzymes and
prevent protein denaturation when in the presence of stress (Fig.4). This increase has
been seen in previous rabbit models of cardiac ischemia (Knowlton, 1991). There are
multiple factors that are observed in a failing heart that have been linked with increases
of Hsp70 like TNFα, stretch, and decreased shortening in the ventricles. Hsp70 has been
show to interact in the caspase pathway by preventing Apaf-1 from recruiting caspase-9
in the intrinsic pathway. There is also a caspase independent manner in which Hsp70 has
been shown to inhibit apoptosis. That way involves Hsp70’s ability to inhibit c-Jun Nterminal kinase, which is used in apoptosis. However, the caspase independent manner
that Hsp70 can work by has yet to be studied in cardiac tissue (Latchman, 2001). Over
14

Figure 4
The Role of Hsp70. Heat shock protein 70 recognizes unfolded and misfolded proteins.
Heat shock protein 70 then reacts with them and by using ATP can restore them back to
their native state.
Adapted from Wilhelmus, 2007.
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an elongated period of time the recruitment of Hsp70 is lessened due to this constant
stimulation and it then becomes less and less effective over time (Knowlton 1998). The
body’s natural reaction to curb the use of Hsp70 can be over-ridden and when Hsp70 is
over expressed it is able to protect against ischemia from occurring (Li, 1991).

Changes in the Extracellular Matrix
The extracellular matrix (ECM) is a collection of fibrillar collagen, elastin,
microfibrillar proteins, proteoglycans, and adhesive proteins used to support the three
dimensional structure of most cells. The ECM is a structure that under different
conditions can alter its own composition to adapt to those stimuli. In the myocardium of
the heart the ECM is mostly composed of fibrillar collagen. The restructuring of the
components in fibrillar collagen is thought to play a part in ventricular remodeling. A
typical response to injury such as heart failure is to increase the amount of collagen and
reinforce the area. The accumulation of myocardial collagen can lead to myocardial
fibrosis. The left ventricular dilation that causes cellular hypertrophy is also associated
with myocardial fibrosis. As heart failure progresses, the activation of matrix
metalloproteinases (MMP) becomes an important part of myocardial matrix remodeling.
These zinc-dependant enzymes degrade the ECM during remodeling and triggers left
ventricular dilation, wall thinning, and cardiac dysfunction. Of the different MMP
species, MMP-9 is one that has been commonly associated with heart failure. MMP-9 is
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an enzyme that degrades collagen types I, II, and III. A chronic heart failure study in
mice showed that the deletion of the gene encoding MMP-9 attenuated left ventricular
dilation and the accumulation of collagen. This shows the effects that activation of
MMP-9 can have on hastening the progression of heart failure (Ducharme, 2000). The
reasoning behind how MMP-9 is involved in the progression of heart failure lies in the
fact that it breaks down the collagen in the ECM. In response to this breakdown more
collagen is synthesized and eventually this exceeds the rate of degradation leading to an
accumulation of oxidized ECM. As the ECM accumulates, the distance between
myocytes increases and that negatively affects the contractility of the heart and its overall
function (Ovechkin, 2005).

Oxidative Stress Results of Heart Failure
During heart failure there is degradation in the proper contractility and overall
function of the ventricles. This ventricular dysfunction leads to improper oxygen supply
to the myocardial tissue as well as a loss of contractile myocytes. During the progression
of heart failure these factors lead to exaggerated levels of oxidative stress produced by
various cytokines and growth factors. The results of oxidative stress are the creation of
harmful reactive oxygen species. Superoxide dismutase (SOD) is an early defense
mechanism to scavenge superoxide anions (O2·), which occur under normal conditions in
the body and increase under environmental factors that cause stress. Since reactive
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oxygen species, such as O2·, occur naturally there is also a normal level of SOD that is
always present, but in the heart this level is normally low. As there is an increase in
oxidative stress from heart failure from ventricular dilation there is an increase in the
amount of SOD that is needed to scavenge the free O2·. It is important for this to occur
because O2· is able to cause cellular death by binding to DNA, protein, and lipids
(Casserot and Doul). The result of SOD is the creation of oxygen (O2) and hydrogen
peroxide (H2O2), which are the body’s primary cellular defense against the formation of
O2· (Fig. 5). Once this reaction occurs there is a need for further reactions since the
newly created H2O2 is also a reactive oxygen species, although not as effective as O2· is
in harming cells. As these reactions continue to occur during heart failure the antioxidant
reserve is slowly being compromised. As this reserve is compromised, the myocytes and
the extra cellular matrix of the heart are predisposed to more damage (Haibo, 2007).
Oxidative stress has also been linked to another route of apoptosis involving the
production of TNF. TNF is a proinflammatory cytokine that is associated with cardiac
dysfunction. A previous study linked the relationship between H2O2 and oxidantsensitive proteins that could initiate the production of TNF. The study showed that H2O2
was able to induce TNF production even without ischemia and reperfusion (Meldrum,
1998). One possibility for this link is that physical forces such as ventricular dilation
during heart failure release cytokines and growth factors that may induce the production
of reactive oxygen species. One study saw an increase in superoxide production under
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Figure 5
Superoxide Dismutase Reaction. Superoxide dismutase reacts with harmful superoxide
anions to create oxygen and hydrogen peroxide. This process is increased in response to
oxidative stress that is brought on by heart failure.
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2 O2· + 2 H+ → H2O2 + O2
SOD
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conditions of high tension in the heart. The study also saw an increase in the expression
of the Fas receptor protein, a member of the TNF family, in the myocytes. The
conclusion was that there was a link between the generation of reactive oxygen species
and the activation of genes that lead to cell death by apoptosis (Cheng, 1995). Other
studies have come out more recently confirming that an increase in reactive oxygen
species is an important determinant in activating the apoptotic cascade. Initially a small
increase in the amount reactive oxygen species present assisted in causing hypertrophy,
and then as the amount increases the occurrence of apoptosis becomes more prevalent.
This study also showed that stretch induced in ventricular myocytes caused an increase in
superoxide anion production (Pimentel, 2001). Oxidative stress is a good marker to use
because it can be shown as an early marker in two main causes of heart failure; stress
related and pro-apoptotic signaling.

Specific Aims
This thesis will test the following hypothesis: The non-blood contacting direct
mechanical ventricular actuation device (DMVA) can improve ventricular pump function
of the failing rabbit heart while attenuating maladaptive cell signaling that characterizes
heart failure.
This thesis will be accomplished by using the following specific aims:
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1.

The use of a DMVA device is able to reduce the myocardial stress that occurs

during heart failure.
a)

The expression of Hsp70 will be evaluated by immunoblotting. This will

evaluate the amount of stress and stretch that is being exerted on the ventricles at each
stage.
b)

The activity of superoxide dismutase will be determined by an activity

assay. Increases in superoxide dismutase are an early signal that there is an increase in
oxidative stress.
2.

The DMVA device will impede pro-apoptotic cellular signaling.
a)

The extrinsic pathway of apoptosis will be analyzed through the

expression of TNFR and caspase-8 will be evaluated by immunoblotting and fluorimetric
activation. Both of these components are upstream activators of the extrinsic caspase
cascade involved in apoptosis. Due to the short duration of the experiment these
upstream activators are the most reliable to see early changes in protein expression.
b)

The intrinsic pathway of apoptosis will be analyzed through the expression

of caspase-9 and will be evaluated by immunoblotting. Caspase-9 represents the furthest
upstream caspase in the intrinsic pathway of apoptosis.
3.

The use of DMVA will attenuate the stress placed on the extracellular matrix.
a)

The activation of MMP-9 will be evaluated by immunoblotting and an

activity assay. The activation of MMP-9 evaluates the breakdown of the ECM of the
ventricles due to the dysfunction of loading and unloading during heart failure.
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II. Materials and Methods
Rabbit Surgery
New Zealand White Rabbits (4-5 kg) were to be randomly chosen to undergo one
of three procedures; a control group receiving no surgery or induction of heart failure,
have heart failure induced for a set amount of time with no assistance, or have heart
failure induced for a set amount of time with the assistance of direct mechanical
ventricular actuation (DMVA). In the control group six rabbits were euthanized and the
hearts were extirpated immediately and quick frozen to be stored at -80ºC until needed.
The remaining animals, ranging from 5 to 7 animals per sample group, underwent the
same initial procedures to induce heart failure. Anesthesia was induced by using 1-2.5%
isoflurane in oxygen, given by way of a mask and maintained throughout the procedure.
Once the animal was anesthetized incisions were made on the hind legs and femoral
intravenous lines were put in place. These lines were used to maintain proper doses of
phenylephrine and esmolol, which were used to maintain blood pressure and to simulate
heart failure by decreasing cardiac output. A Millar catheter (Millar Instruments,
Houston, TX) was inserted into the internal carotid artery for measuring arterial pressure.
A median sternotomy was performed and an ultrasonic flow probe (Transonic Systems,
Ithaca, NY) was positioned on the ascending aorta for measuring cardiac output.
Electrocardiogram, hemodynamics, pulse oximetery, end-tidal CO2, and rectal
temperature were recorded with a LifeWindow 6000 system (Digicare, Boynton Beach,
FL).
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Once all instrumentation was in place a baseline cardiac output was determined
from the flow probes. From that reading a value 60% of the baseline was considered
“heart failure” for that animal. Phenylephrine was administered intravenously to
maintain a mean arterial pressure between 40mmHg and 50 mmHg. To induce heart
failure esmolol, a short acting beta blocker, was also administered intravenously both
with a running dose and by using boluses to maintain the heart failure state. At this point
the treated animals were either kept in the heart failure state for 30 minutes, 60 minutes,
or 120 minutes, or could receive DMVA assistance by means of the Myovad cup used for
this study. The total duration of the cup treatment was also for 30 minutes, 60 minutes,
or 120 minutes, each a doubling of the previous time frame. During the DMVA studies,
the cup was to be removed every 15 minutes for observation of the heart to ensure that
the equipment was working properly and that the animal remained in the heart failure
state, if the rabbit was no longer in the “heart failure” state the appropriate adjustments
were made to the infusion of esmolol and phenylephrine to again reach that point and the
trial would continue. The action of removing the cup may have caused some additional
trauma by removing and reattaching, but this was necessary to maintain the integrity of
the heart failure state. Once a study had reached the necessary time span the animals
were then observed for 30 minutes in a recovery state. During this recovery state the
esmolol was no longer administered, but general anesthesia continued to be administered
and those parameters continued to be measured. At all points during the surgery
echocardiography was used to monitor each phase of the experiment. Once the recovery
period was over the animals were euthanized under deep anesthesia, 5% isoflurane, by
extirpating the hearts. The hearts were sliced into six sections laterally and quick frozen
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in isopentane cooled in liquid nitrogen for fixation and future study.
In this study two distinct groups were analyzed, the acute group and the extended
support/failure group. The acute group was made up of the sham group and the 30
minute groups of heart failure with or without DMVA assistance. The extended
support/failure model was comprised of the 60 minute and the 120 minute groups of heart
failure with or without DMVA assistance. It was necessary to separate the acute model
from the extended support/failure model to eliminate the possible differences in cellular
response to apoptosis due to those time differences.

Protein Extraction
Tissue was thawed and then homogenized with 300 µl T-PER Tissue Protein
Extraction Reagent (Pierce), 10 µl Halt Protease Inhibitor Cocktail Kit (Pierce), 3 µl
EDTA (Pierce), and 3 µl PMSF (Pierce), then centrifuged at 13,000 RPM for 5 minutes.
The supernatant was recovered from the homogenate and the protein concentrations of
the supernatant was determined by using the Bradford method (BioRad Laboratories,
Hercules, CA) (138).

Immunoblotting
Each sample was loaded on SDS-Page 12% Tris-HCl Ready gel, 8.6 x 6.8 cm
(BioRad Laboratories, Hercules, CA), and run on electrophoresis at 80 volts for 20
minutes and then at 180 volts until the dye front nears the bottom of the gel. Each gel
was loaded according to time duration to better directly compare the difference of heart
failure versus direct mechanical ventricular actuation at each time point. Proteins were
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transferred from the gel to a PVDF Immobilon-P transfer membrane (Millipore) using
semi-dry transfer with a Trans-Blot SD (Biorad) at 20 volts for one hour. The PVDF
membranes were blocked with 5% Non-fat dry milk in tris buffered saline with 5%
Tween-20 (TBSTB). Then they were incubated with the primary antibody, either tumor
necrosis factor receptor I, heat shock protein 70, caspase-8, caspase-9, or glyceraldehyde
3 phosphate dehydrogenase, diluted to the optimal amount in TBSTB for two hours.
Membranes were then washed three more times with TBST and then probed with the
secondary horseradish peroxidase linked antibody (antibody specific to marker) diluted in
TBSTB. Then there will be three more washes of the membrane with TBST. Samples
were visualized via enhanced chemiluminescence substrate (Pierce) and captured by the
Fuji LAS3000 imager. The relative amount of protein of interest was determined by
normalizing that protein to glyceraldehyde 3 phosphate dehydrogenase. Glyceraldehyde
3 phosphate Dehydrogenase is considered a housekeeping gene that is expressed in most
tissues and cells, making it appropriate as a control. Actin was not used due to its
relation to the contractile apparatus in muscle cells, which may be affected during heart
failure.

Protein Transfer Analysis
To evaluate the ability of the total protein to effectively transfer from the TrisHCl gel to the membrane, tests were run with the gel and the membrane. First the semidry transfer method was evaluated by running a time course transfer. For this a gel was
loaded with three different amounts of total protein; 15µg, 30µg, and 45µg. Lanes were
set up so that 15µg was in lane four, 30µg was in lane five, and 45µg was in lane six.
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Lanes 8-10 and 12-14 mirrored the set up from lanes 4-6. Gel was run as described
previously in western blotting. Before the gel was run in the semi-dry, transfer lanes 1-7
were removed and stained in Coomasie Blue to visualize the amount of protein that ran
through the gel. The remaining gel was run in the semi-dry transfer method for one hour.
At that point lanes 8-11 were removed and placed in Coomasie Blue stain. The remaining
gel continued to run for one additional hour and was also stained in the Coomasie Blue.
The other test run to evaluate transfer efficiency was to stain the membrane after
the semi–dry transfer to visualize the amount of protein retained on the membrane. To do
this a gel was run with different concentrations and transferred for one hour. The
resulting membrane was incubated in Ponceau S stain (Pierce) for 10 minutes. This was
followed by three washes of five minutes with 20% acetic acid to remove any excess
stain. The resulting protein was analyzed visually.

Caspase-8 Activity Assays
Tissues were thawed and then homogenized with 200 µl of lysis buffer
provided by Sigma with the Caspase-8 assay kit containing 25mM HEPES, pH 7.4,
5mM CHAPS, and 5mM DTT. The resulting homogenate was then centrifuged at
13,000 RPM for 5 minutes. The supernatant was recovered from the homogenate and the
protein concentrations of the supernatant were determined by using the Bradford method
(BioRad Laboratories, Hercules, CA) (138).
The reaction was carried out in a 96-well plate. Each well was designated as a
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blank, positive control, positive control plus the inhibitor, or sample. The blank well
contained 90ul of the assay buffer; 20mM HEPES, pH 7.4, 0.1% CHAPS, 5mM DTT,
2mM EDTA, and 5% sucrose. The positive control contained 5ul of 10ug/ml caspase-8
along with 85ul assay buffer. The positive control plus the inhibitor contained 5ul of
caspase-8 and 83ul of assay buffer along with 2ul of caspase-8 inhibitor, 25uM Ac-IEDTCHO. The samples were loaded according to the protein content of the sample so that
there was 400ug of protein per sample per well. The amount of assay buffer added to a
given sample was 90ul minus the amount of sample already in the well so that the total in
the well was 90ul. The reaction was initiated with 10ul of the caspase-8 substrate made
of 1.5mM Ac-IETD-AMC in DMSO that was also diluted 10-fold with the assay buffer
prior to the experiment. The reaction is defined by the hydrolysis of the caspase-8
substrate by the caspase-8 in the samples resulting in the release of AMC. The AMC
released can then be measured by fluorimetric detection by using 360nm as the excitation
wavelength and 440nm as the emission wavelength. A calibration curve using known
amounts of AMC was run with each test and used to determine the amount of nmols of
AMC that was released per minute, per milligram of protein in each sample.
A kinetic measurement was obtained by allowing the reaction to carry on for 70
minutes. At that point the difference between the starting relative fluorescence and the
ending fluorescence was used to determine the amount of nmols of AMC that were
released from the sample by using the calibration curve. That value was divided by the
duration of the experiment and the total amount of protein to get the activity value,
defined as nmols of AMC released per minute per milligram of protein.
To validate that the reaction that was occurring with the samples was indeed the
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release of AMC by caspase-8, a test was run to verify this. Confirmation was obtained by
running samples in duplicate where one sample was run as described before and the other
contained 2ul of the inhibitor of caspase-8. A positive result would show a significant
decrease in the activity in the sample containing the inhibitor when compared directly to
the same sample run simultaneously without any inhibitor.

Superoxide Dismutase Activity Assay
Tissues were thawed and then homogenized with 200 µl of 1X cell extraction
buffer provided in Assay Designs kit for superoxide dismutase (SOD), which contained
10X SOD buffer, 20% (v/v) Triton X-100, distilled water, and 200mM PMSF. The
resulting homogenate was then centrifuged at 11,000 x g for 10 minutes at 4°C. The
supernatant was recovered from the homogenate and the protein concentrations of the
supernatant were determined by using the Bradford method (BioRad Laboratories,
Hercules, and CA).
The SOD reaction was carried out in a 96-well plate. Each well was designated as
a blank, standard control, or sample. The blank well contained 25ul of 1X SOD buffer,
150ul of the master mix (containing 10X SOD Buffer, WST-1 reagent, xanthine oxidase,
and distilled water), and 25ul of 1X xanthine solution (containing 10X xanthine
solution and 1X SOD buffer) to get a total volume of 200ul. The standard control was
prepared according to the design laid out by the insert in the kit. The fifty micrograms of
heart extract were loaded per well and the samples were diluted using master mix so that
there was a total volume of 25ul per well. After 150ul of master mix was added to each
sample well, the reaction was started by adding 25ul of 1X xanthine solution to each
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well. The plate was mixed by orbital shaking for 10 seconds and then read at one minute
increments for twenty minutes at room temperature. The activity was measured by the
absorbance levels at 450nm.
A kinetic measurement was obtained by allowing the reaction to carry on for 20
minutes. At that point the percent inhibition was determined by subtracting the slope of
the sample from the slope of the 1X SOD buffer control, multiplying that by 100 and then
dividing by the slope of the 1X SOD buffer control. The percent inhibition is found due
to the idea that the more SOD present in a sample, the lower the absorbance rate will be.
Since the 1X SOD buffer control contains no SOD it is used as the maximal rate of
absorbance and is considered 100%.

MMP-9 Activity Assay
Tissues samples were thawed and then homogenized in assay buffer (Anaspec)
containing 0.1% Triton-X 100, and then centrifuged for 15 min at 10000x g at 4°C. The
supernatant was recovered from the homogenate and the protein concentrations of the
supernatant were determined by using the Bradford method (BioRad Laboratories,
Hercules, CA) (138).
The MMP-9 activity measurement was carried out in a 96-well plate using 1mM
4-aminophenylmercuric acetate as a substrate in the assay buffer for 2 hours at 37°C prior
to adding the sample. Each sample was loaded at 200ug of protein per 50uL of solution.
This was added to each well to start the reaction and the plate was incubated at room
temperature for 10 minutes. The enzymatic reaction was initiated by adding 50ul of
MMP-9 substrate (Anaspec) to each well and then the plate was shaken for 30 seconds
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before measuring the fluorescence intensity using excitation at 340nm and emission at
490nm, continuous recording every 5 minutes for 60 minutes total. Rates were
determined by taking the slope of the reactions and correcting for time.

MMP-9 Zymography
Heat tissues were homogenized in an extraction buffer (62.5 mM Tris-HCl pH
6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol) for use in protease analysis.
Various amounts of total protein, ranging from 5ug-50ug, of each extract dissolved in a
loading buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 4% SDS, 0.01% Bromophenol
Blue, BioRad) provided by the manufacture. Gels were electrophoresed through a 10%
zymogram gel (BioRad) with gelatin in a running buffer (25 mM Tris base, 192 mM
glycine, 0.1% SDS with deionized water at pH 8.3) for 90 minutes. The gels were
washed with Zymogram Renaturation Buffer (2.5% Triton X-100, BioRad) 3 times for 10
minutes each then incubated for 24 hours, 36 hours, or 1 week at 37°C in Zymogram
Development Buffer (50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl2, BioRad).
The gels were stained in Zymogram Staining solution of: 0.5% Coomassie R250, 10%
Acetic Acid, 40% methanol. Gels were then destained in a BioRad solution (destaining
solution containing 40% methanol and 10% acetic acid) by washing 3 times for 7
minutes. Activity was identified as clear bands on a blue background.
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Statistical Analysis
Results are presented as means ± S.E.M and compared between sham, heart
failure and DMVA using an unpaired t-test performed with GraphPad Prism 5 software.
Grubb’s test was used to assess for outliers. A difference of P<0.05 was considered
significant.
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III. Results

We tested our working hypothesis that the non-blood contacting ventricular assist
device (VAD) will improve the overall function of the failing rabbit heart while
attenuating maladaptive related cellular signaling using immunoblotting assays with well
known cardiac apoptotic and stress related markers. Staining of these blots enabled us to
determine the effects of heart failure and direct mechanical ventricular actuation
(DMVA) had on the cardiac tissue. We measured other enzyme markers, such as
superoxide dismutase (SOD) and matrix metalloprotease 9 (MMP-9) to assess both
mechanical and chemical initiators of apoptosis in the cardiac tissues receiving heart
failure and DMVA assisted heart failure. Summary tables of all the quantified results can
be found in Appendix A.

Analysis of Protein Loading and Transfer for Immunoblotting
Before measuring the level of marker proteins in cell extracts it was necessary to
determine the sensitivity of our detection method and the kinetics of protein transfer. The
concentration dependence for each marker protein was determined, including the
minimum level of detection and at which concentration was observed. Quantitation of all
marker proteins was run in a corresponding linear range of optical density. The results
showed that proteins such as glyceraldehyde 3 phosphate dehydrogenase (GAPDH),
Cytochrome-C, and tumor necrosis factor receptor (TNFR) were visible at lower load
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amounts of protein, approximately 25ug of protein as determined by the Bradford
Method. The other proteins; Caspase-8, Caspase-9 and Hsp-70 required a larger load
amount to be visible, approximately 40ug of protein as determined by the Bradford
Method (data not shown).
To determine the appropriate time for transfer, a single gel was used for four
different time points, before the transfer, at 1 hour, at 1.5 hours and at 2 hours. Each
resulting gel slice was stained with Coomasie Blue dye to visualize the amount of protein
remaining in the gel at the different time points. The results showed good transfer at all
time points, with increasing amounts of protein transfer as the duration increased. To
confirm these results, the transfer membrane also was stained with Ponceau-S stain to
visualize the amount of protein that had adhered to the membrane. These results together
showed that at 1.5 hours there was sufficient amount of transfer to the membrane.

Tumor Necrosis Factor Receptor Immunoblotting
Tumor Necrosis Factor Receptor (TNFR) is a marker that is seen at the initial
stages of apoptosis. This receptor is activated in the initial stages in the extrinsic pathway
of apoptosis and thus is expected to be a good indicator for an acute heart failure model.
As more receptors reach this activated state the likelihood of a cell to undergo apoptosis
is increased. A rise in TNFR content in the acute model was seen in both the HF and
DMVA groups of the left ventricle when compared to the sham group to a significant
level, suggesting that apoptosis was being initiated in both groups. In the extended
support/failure model, there was a significant increase of approximately 200% from the
60 to the 120 minute groups (Figs. 6-10). There was no difference at the 60 minute point,
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however, at 120 minutes with heart failure there was significantly higher TNFR content
than that in the 120 minute group with DMVA assistance ( 1.74 vs. 1.29, p=0.02). The
45% decrease of TNFR content in heart failure compared to TNFR content in the DMVA
assisted heart failure indicates that the use of DMVA reduces the rate at which proapoptotic signaling is initiating during heart failure in a statistically significant (p=0.03)
manner.
Similar results using anti-TNFR were observed in the right ventricle. There was a
significant increase from both 30 minute groups when compared to the sham group. The
trend in the extended support/failure model showed a steady increase in the TNFR
content as the duration was increased (Figs. 11-15). Within each time point, there was no
significant difference between the heart failure group and the DMVA group at any point.
There was, however, a steady increase in the difference between the heart failure group
and the DMVA group as the time of failure increased. The lack of significant change
between the DMVA and heart failure groups is an indication that the use of DMVA did
not reduce or accentuate the initial signaling for the extrinsic pathway compared to the
heart failure group.
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Figure 6- Immunoblotting Representation of TNFR Content in the Left Ventricle of Sham Acute
Hearts. Immunoblots were performed using 25ug of protein with anti-TNFR antibody at a 1:2000 dilution
to measure the relative protein content as described in the Methods section. Six sham acute hearts are
represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 7- Immunoblotting Representation of TNFR Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 30 Minute Acute Hearts. Western
Immunoblots were performed using 25ug of protein with anti-TNFR antibody at a 1:2000 dilution to
measure the relative protein content as described in the Methods section. In part A, five acute hearts
represented in lanes 1-5 had heart failure induced for 30 minutes and were normalized to GAPDH at a
1:5000 dilution for quantification purposes. In (B), six acute hearts represented in lanes 6-11 had heart
failure induced while receiving direct mechanical ventricular actuation support for 30 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 8- Immunoblotting Representation of TNFR Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 60 Minute Extended Support/Failure
Hearts. Immunoblots were performed using 25ug of protein with anti-TNFR antibody at a 1:2000 dilution
to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 60 minutes and were
normalized to GAPDH at a 1:5000 dilution or quantification purposes. In (B), 7 extended support/failure
hearts represented in lanes 6-12 had heart failure induced while receiving direct mechanical ventricular
actuation support for 60 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 9- Immunoblotting Representation of TNFR Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 25ug of protein with anti-TNFR antibody at
a 1:2000 dilution to measure the relative protein content as described in the Methods section. In (A), five
extended support/failure hearts represented in lanes 1-5 had heart failure induced for 120 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six extended support/failure
hearts represented in lanes 6-11 had heart failure induced while receiving direct mechanical ventricular
actuation support for 120 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 10- Relative TNFR Content in the Left Ventricle in Acute (A) and Extended Support/Failure
(B) Hearts. Values as mean ± SEM of relative protein amount, and * P<0.0002 30 HF vs. sham,
**P<0.0001 30 DMVA vs. sham, †P<0.0001 120 HF vs. 60 HF, and ††P<0.0003 120 DMVA vs. 60HF
and P<0.02 120 DMVA vs. 120 HF. In (A), data are presented from six acute hearts for the direct
mechanical ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure
(HF) trial. In (B), data are presented from five extended support/failure hearts for each HF trial, seven
extended support/failure hearts for the 60 DMVA trial and six extended support/failure hearts for the 120
DMVA trial.
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Figure 11- Immunoblotting Representation of TNFR Content in the Right Ventricle of Sham Acute
Hearts. Immunoblots were performed using 25ug of protein with anti-TNFR antibody at a 1:2000 dilution
to measure the relative protein content as described in the Methods section. Six sham acute hearts are
represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 12- Immunoblotting Representation of TNFR Content in the Right Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 30 Minute Acute Hearts.
Immunoblots were performed using 25ug of protein with anti-TNFR antibody at a 1:2000 dilution to
measure the relative protein content as described in the Methods section. In (A), five acute hearts
represented in lanes 1-5 had heart failure induced for 30 minutes and were normalized to GAPDH at a
1:5000 dilution for quantification purposes. In (B), six acute hearts represented in lanes 6-11 had heart
failure induced while receiving direct mechanical ventricular actuation support for 30 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 13- Immunoblotting Representation of TNFR Content in the Right Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 60 Minute Extended Support/Failure
Hearts. Immunoblots were performed using 25ug of protein with anti-TNFR antibody at a 1:2000 dilution
to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 60 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), seven extended
support/failure hearts represented in lanes 6-12 had heart failure induced while receiving direct mechanical
ventricular actuation support for 60 minutes and were normalized to GAPDH at a 1:5000 dilution for
quantification purposes.
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Figure 14- Immunoblotting Representation of TNFR Content in the Right Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 25ug of protein with anti-TNFR antibody at
a 1:2000 dilution to measure the relative protein content as described in the Methods section. In (A), five
extended support/failure hearts represented in lanes 1-5 had heart failure induced for 120 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six extended support/failure
hearts represented in lanes 6-11 had heart failure induced while receiving direct mechanical ventricular
actuation support for 120 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 15- Relative TNFR Content in the Right Ventricle in Acute (A) and Extended Support/Failure
(B) Hearts. Values as mean ± SEM of relative protein amount, and the * P<0.02 30 HF vs. sham,
**P<0.03 30 HF vs. sham, and †P<0.01 120 HF and 120 DMVA vs. 60 HF. In (A), data are presented
from six acute hearts for the direct mechanical ventricular actuation (DMVA) trial and sham trial, and five
acute hearts for the heart failure (HF) trial. In (B), data are presented from five extended support/failure
hearts for each HF trial, seven extended support/failure hearts for the 60 DMVA trial and six extended
support/failure hearts for the 120 DMVA trial.
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Measurement of Heat Shock Protein 70 Content in Hearts
Heat Shock Protein 70 (Hsp70) is a marker related to mechanical stretch of
myocardial cells that is seen in cardiac failure. Since Hsp70 is an early indicator of stress
from cardiac tissue stretch it can be used to monitor initial stages of failure and also
assess if the DMVA assistance decreased heart muscle stretch. There was an increase in
the Hsp70 content in the left ventricle in both 30 minute groups as compared to the sham
group. A significant trend occurred in each group as the duration of the treatment
became longer. Within the 30 minute period, there was no significant difference seen in
Hsp70 content between the 30 minute period heart failure and the 30 minute DMVA. At
the 60 minute point, there was a significant difference between the groups with heart
failure exhibiting a 61.5% increase in Hsp70 content as compared to DMVA (0.52 vs.
0.32, p=0.02). The content of Hsp70 in the 120 minute group also showed an increase
with heart failure having a higher content than DMVA by about 46.6% (1.54 vs. 1.05,
p=0.04) (Figs. 16-20). The increases in the longer time periods of the studies strongly
suggest that the use of DMVA assistance is effective in reducing myocardial stretch
during heart failure. In turn, this is a positive sign that the tissues are more likely to
remain intact and be better suited to recover from the heart failure when supported by
DMVA.
The right ventricle has lower tensile strength and muscle volume when compared
to the left ventricle and is thus more susceptible to problems arising due to mechanical
stress. These characteristics created a greater challenge for the DMVA device to
overcome and exhibit noticeable benefits during heart failure. In the right ventricle there
was no change in the content of Hsp70 between both 30 minute groups and the sham
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group. The 60 minute time point also had no significant differences between HF and
DMVA. However, there was a significant increase in both 120 minute groups when
compared to the 60 HF group, increases of 100% in DMVA (0.34 vs. 0.17, p=0.02) and
124% in the HF group (0.38 vs. 0.17, p=0.001) (Figs. 21-25). No single time point
exhibited a significant difference between the Hsp70 content of the heart failure group
versus the DMVA group. The right ventricle showed signs of increased HSP70
activation in both groups as the duration increased. Although the use of DMVA did not
attenuate the activation of Hsp70 in the right ventricle, it also did not show any signs of
increasing the activation of Hsp70 either.
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Figure 16- Immunoblotting Representation of Hsp70 Content in the Left Ventricle of Sham Acute
Hearts. Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at a dilution of
1:2000 to measure the relative protein content as described in the Methods section. Six sham acute hearts
are represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification purposes.

59

60

Figure 17- Immunoblotting Representation of Hsp70 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 30 Minute Acute Hearts.
Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at a dilution of 1:2000 to
measure the relative protein content as described in the Methods section. In (A), five acute hearts
represented in lanes 1-5 had heart failure induced for 30 minutes and were normalized to GAPDH at a
1:5000 dilution for quantification purposes. In (B), six acute hearts represented in lanes 6-11 had heart
failure induced while receiving direct mechanical ventricular actuation support for 30 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 18- Immunoblotting Representation of Hsp70 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 60 Minute Extended Support/Failure
Hearts. Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at a dilution of
1:2000 to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 60 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), seven extended
support/failure hearts represented in lanes 6-12 had heart failure induced while receiving direct mechanical
ventricular actuation support for 60 minutes and were normalized to GAPDH at a 1:5000 dilution for
quantification purposes.
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Figure 19- Immunoblotting Representation of Hsp70 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at
a dilution of 1:2000 to measure the relative protein content as described in the Methods section. In (A),
five extended support/failure hearts represented in lanes 1-5 had heart failure induced for 120 minutes and
were normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six extended
support/failure hearts represented in lanes 6-11 had heart failure induced while receiving direct mechanical
ventricular actuation support for 120 minutes and were normalized to GAPDH at a 1:5000 dilution for
quantification purposes.
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Figure 20- Relative Hsp70 Content in the Left Ventricle in Acute (A) and Extended Support/Failure
(B) Hearts. Values as mean ± SEM of relative protein amount, and *P<0.001 30 HF vs. Sham, **P<0.005
30 DMVA vs. Sham, †P<0.02 60 DMVA vs. 60 HF, ††P<0.001 120 HF vs. 60 HF, and ‡P<0.04 120
DMVA vs. 120 HF and PP<0.001 120 DMVA vs. 60 HF. In (A), data are presented from six acute hearts
for the direct mechanical ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the
heart failure (HF) trial. In (B), data are presented from five extended support/failure hearts for each HF
trial, seven extended support/failure hearts for the 60 DMVA trial and six extended support/failure hearts
for the 120 DMVA trial.
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Figure 21- Immunoblotting Representation of Hsp70 Content in the Right Ventricle of Sham Acute
Hearts. Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at a dilution of
1:2000 to measure the relative protein content as described in the Methods section. Six sham acute hearts
are represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 22- Immunoblotting Representation of Hsp70 Content in the Right Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 30 Minute Acute Hearts.
Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at a dilution of 1:2000 to
measure the relative protein content as described in the Methods section. In (A), five acute hearts
represented in lanes 1-5 had heart failure induced for 30 minutes and were normalized to GAPDH at a
1:5000 dilution for quantification purposes. In (B), six acute hearts represented in lanes 6-11 had heart
failure induced while receiving direct mechanical ventricular actuation support for 30 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 23- Immunoblotting Representation of Hsp70 Content in the Right Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 60 Minute Extended Support/Failure
Hearts. Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at a dilution of
1:2000 to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 60 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), seven extended
support/failure hearts represented in lanes 6-12 had heart failure induced while receiving direct mechanical
ventricular actuation support for 60 minutes and were normalized to GAPDH at a 1:5000 dilution for
quantification purposes.
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Figure 24- Immunoblotting Representation of Hsp70 Content in the Right Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 40ug of protein with anti-Hsp70 antibody at
a dilution of 1:2000 to measure the relative protein content as described in the Methods section. In (A), five
extended support/failure hearts represented in lanes 1-5 had heart failure induced for 120 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six extended support/failure
hearts represented in lanes 6-11 had heart failure induced while receiving direct mechanical ventricular
actuation support for 120 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 25- Relative Hsp70 Content in the Right Ventricle in Acute (A) and Extended Support/Failure
(B) Hearts. Values as mean ± SEM of relative protein amount, and *P<0.001 120 HF vs. 60 HF and
**P<0.02 120 DMVA vs. 60 HF. In (A), data are presented from six acute hearts for the direct mechanical
ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure (HF) trial. In
(B), data are presented from five extended support/failure hearts for each HF trial, seven extended
support/failure hearts for the 60 DMVA trial and six extended support/failure hearts for the 120 DMVA
trial.
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Caspase-8 Immunoblotting in the Left Ventricle
Caspase-8 is another marker for the extrinsic pathway of apoptosis. Caspase-8
was used as a marker to examine how the activation of the TNFR was being translated
downstream in the signaling cascade (Fig. 3). Caspase-8 is activated after the appropriate
amount of TNFR is activated causing it to auto-cleave from the inactive pro-caspase
form. The activation of caspase-8 would further show if pro-apoptotic signaling is
continuing to be activated along the extrinsic pathway. Immunoblotting was not run on
right ventricle samples due to the discontinuation of the caspase-8 antibody being used.
Since caspase-8 activation is a process where different segments are cleaved from the
inactive pro-form, the activated segment at about 45kds is commonly observed as the
marker for caspase-8 activation. In the acute model, there was no difference between the
sham and both 30 minute groups (heart failure and DMVA assisted). In the extended
support/failure model, there was no difference between both 60 minute groups and the
120 minute DMVA group (Figs. 26-30). However, the 120 minute heart failure exhibited
a significant increase from both 120 minute DMVA supported tissue by 71.9% (0.98 vs.
0.57, p=0.02) and the 60 minute HF group by 88.5% (0.98 vs. 0.52, p=0.0006). These
increases indicate that pre-apoptotic events are occurring in the heart failure model, but
the DMVA assistance slows the activation of caspase-8. Thus, it can be concluded from
these results that the use of DMVA is attenuating the left ventricle from continuing along
the extrinsic pathway of pro-apoptotic events.
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Figure 26- Immunoblotting Representation of Caspase-8 Content in the Left Ventricle of Sham Acute
Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase-8 antibody at a dilution of
1:500 to measure the relative protein content as described in the Methods section. Six sham acute hearts
are represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification purposes.

80

81

Figure 27- Immunoblotting Representation of Caspase-8 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 30 Minute Acute Hearts.
Immunoblots were performed using 40ug of protein with anti-Caspase-8 antibody at a dilution of 1:500 to
measure the relative protein content as described in the Methods section. In (A), five acute hearts
represented in lanes 1-5 had heart failure induced for 30 minutes and were normalized to GAPDH at a
1:5000 dilution for quantification purposes. In (B), six acute hearts represented in lanes 6-11 had heart
failure induced while receiving direct mechanical ventricular actuation support for 30 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 28- Immunoblotting Representation of Caspase-8 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 60 Minute Extended Support/Failure
Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase-8 antibody at a dilution of
1:500 to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 60 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), seven extended
support/failure hearts represented in lanes 6-12 had heart failure induced while receiving direct mechanical
ventricular actuation support for 60 minutes and were normalized to GAPDH at a 1:5000 dilution for
quantification purposes.
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Figure 29- Immunoblotting Representation of Caspase-8 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase-8
antibody at a dilution of 1:500 to measure the relative protein content as described in the Methods section.
In (A), five extended support/failure hearts represented in lanes 1-5 had heart failure induced for 120
minutes and were normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six
extended support/failure hearts represented in lanes 6-11 had heart failure induced while receiving direct
mechanical ventricular actuation support for 120 minutes and were normalized to GAPDH at a 1:5000
dilution for quantification purposes.
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Figure 30- Relative Caspase-8 Content in the Left Ventricle in Acute (A) and Extended
Support/Failure (B) Hearts. Values as mean ± SEM of relative protein amount, and *P<0.0006 120 HF
vs. 60 HF and **P<0.02 120 DMVA vs. 120 HF. In (A), data are presented from six acute hearts for the
direct mechanical ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the heart
failure (HF) trial. In (B), data are presented from five extended support/failure hearts for each HF trial,
seven extended support/failure hearts for the 60 DMVA trial and six extended support/failure hearts for the
120 DMVA trial.
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Caspase-8 Enzyme Activity Assay
An enzymatic assay specifically for caspase-8 was used to substitute the results
shown in the immunoblotting assays. The benefit of this assay is that it showed only the
enzymatically active caspase-8. The left ventricle exhibited an initial decrease in the
caspase-8 enzymatic activity for both 30 minute groups when compared to sham, the 30
minute DMVA was significantly less (0.005 nmol/min/mg vs. 0.002 nmol/min/mg,
p=0.02). At 60 minutes, DMVA had slightly higher caspase-8 activity when compared to
heart failure, but not to a significant level. By 120 minute treatment time, the heart
failure group exhibited an increased activity that was significantly higher than the DMVA
group by 48% (0.008 nmol/min/mg vs. 0.005 nmol/min/mg, p=0.01) (Fig 31). These
results confirmed the immunoblotting assay (Figs 26-30); in that caspase-8 levels were
increasing consistently with time in heart failure, but not with DMVA assistance. This
enzyme assay shows that the use of DMVA assistance attenuates the extrinsic pathway of
pro-apoptotic signaling in the left ventricle.
The right ventricle was also assayed for caspase-8 activity, giving a more
downstream look at the extrinsic pathway. The 30 minute heart failure group exhibited a
37% increase in caspase-8 activity in heart failure when compared to heart failure with
DMVA (0.005 nmol/min/mg vs. 0.004 nmol/min/mg, p=0.14), but not significant when
compared to the sham group. Within the different treatment time points there was no
significant difference seen, but there was a consistent pattern of the DMVA group
showing slightly less amounts of active caspase-8 activity (Fig 32). 120 minute DMVA
treated tissue did exhibit a significant increase in activity when compared to the 60
minute heart failure (0.004 nmol/min/mg vs. 0.005 nmol/min/mg, p=0.03).
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Figure 31- Relative Caspase-8 Activity in the Left Ventricle in an Acute (A) and Extended
Support/Failure (B) Hearts. Values as mean ± SEM of caspase-8 activity), and * P<0.02 30 DMVA vs.
sham and P<0.03 30 DMVA vs. 30 HF, ** P<0.008 120 DMVA vs. 120 HF, †P<0.01 120 HF vs. 60HF. A
Caspase-8 activity assay kit was run twice to get the average of the relative activity as described in the
Methods section. In (A), data are presented from six acute hearts for the direct mechanical ventricular
actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure (HF) trial. In (B), data are
presented from five extended support/failure hearts for each HF trial, seven extended support/failure hearts
for the 60 DMVA trial and six extended support/failure hearts for the 120 DMVA trial.
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Figure 32- Relative Caspase-8 Activity in the Right Ventricle in an Acute (A) and Extended
Support/Failure (B) Hearts. Values as mean ± SEM of relative protein amount, and * P<0.03 120
DMVA vs. 60 HF. A Caspase-8 activity assay kit was run twice to get the average of the relative activity
as described in the Methods section. In (A), data are presented from six acute hearts for the direct
mechanical ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure
(HF) trial. In (B), data are presented from five extended support/failure hearts for each HF trial, seven
extended support/failure hearts for the 60 DMVA trial and six extended support/failure hearts for the 120
DMVA trials.
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Caspase-9 Immunoblotting
Caspase-9 assesses the rate of apoptosis through the intrinsic pathway during
heart failure. Since it is a more downstream marker in the intrinsic pathway (Fig. 2),
caspase-9 represents a late stage initiator in the apoptotic pathway. The left ventricle saw
no change in caspase-9 content in both 30 minute groups as compared to the sham group.
At 60 minutes there was no difference between heart failure and DMVA assistance. By
120 minutes, caspase-9 content in both groups had increased drastically and was
significantly higher in content than the 60 minute heart failure group, about a 78%
increase in the 120 minute heart failure (0.09 vs. 0.16, p=0.01) and 67% increase in the
120 minute with DMVA assistance (0.09 vs. 0.15, p=0.02) (Fig 33-37). Again, there was
strong evidence pro-apoptotic events were continuing at a steady rate throughout the time
points measured. Additionally, there was no evidence that the use of DMVA was able to
attenuate the advancement of pro-apoptotic events in the left ventricle through the
intrinsic pathway as measured by caspase-9 content.
In the right ventricle the sham group saw no change in the caspase-9 content
between the 30 minute heart failure or DMVA assisted groups. There were also no
differences between the 60 minute groups or between the 120 minute groups (Fig 38-42).
There was, however, an 83% increase measured from 60 minutes to 120 minutes in both
groups, but neither was to a statistically significant level. The right ventricle showed the
same trend as the left ventricle as far as caspase-9 content over the various time points.
For the right ventricle the increase from 60 minute HF to both 120 minute groups gave a
p-value of about 0.08, showing the proximity to statistical significance. The results from
both ventricles was also able to show the effectiveness of the model to induce pro-
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apoptotic events during heart failure Although DMVA did not show any benefits in this
assay, it is also important to note that the use of DMVA assistance did not cause any
further increase in pro-apoptotic events as measured by caspase-9 content.
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Figure 33- Immunoblotting Representation of Caspase-9 Content in the Left Ventricle of Sham Acute
Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase-9 antibody to measure the
relative protein content as described in the Methods section. Six sham acute hearts are represented in lanes
1-6, each normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 34- Immunoblotting Representation of Caspase-9 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 30 Minute Acute Hearts.
Immunoblots were performed using 40ug of protein with anti-Caspase-9 antibody to measure the relative
protein content as described in the Methods section. In (A), five acute hearts represented in lanes 1-5 had
heart failure induced for 30 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes. In (B), six acute hearts represented in lanes 6-11 had heart failure induced while receiving direct
mechanical ventricular actuation support for 30 minutes and were normalized to GAPDH at a 1:5000
dilution for quantification purposes.
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Figure 35- Immunoblotting Representation of Caspase-9 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 60 Minute Extended Support/Failure
Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase-9 antibody to measure the
relative protein content as described in the Methods section. In (A), five extended support/failure hearts
represented in lanes 1-5 had heart failure induced for 60 minutes and were normalized to GAPDH at a
1:5000 dilution for quantification purposes. In (B), seven extended support/failure hearts represented in
lanes 6-12 had heart failure induced while receiving direct mechanical ventricular actuation support for 60
minutes and were normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 36- Immunoblotting Representation of Caspase-9 Content in the Left Ventricle During Heart
Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase9antibody to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 120 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six extended support/failure
hearts represented in lanes 6-11 had heart failure induced while receiving direct mechanical ventricular
actuation support for 120 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 37- Relative Caspase-9 Content in the Left Ventricle in Acute (A) and Extended
Support/Failure (B) Hearts. Values as mean ± SEM of relative protein amount, and *P<0.01 120 HF vs.
60 HF and ** P<0.02 120 DMVA vs. 60 HF. In (A), data are presented from six acute hearts for the direct
mechanical ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure
(HF) trial. In (B), data are presented from five extended support/failure hearts for each HF trial, seven
extended support/failure hearts for the 60 DMVA trial and six extended support/failure hearts for the 120
DMVA trial.
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Figure 38- Immunoblotting Representation of Caspase-9 Content in the Right Ventricle of Sham
Acute Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase-9 antibody to
measure the relative protein content as described in the Methods section. Six sham acute hearts are
represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification purposes.
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Figure 39- Immunoblotting Representation of Caspase-9 Content in the Right Ventricle During
Heart Failure (A) and Direct Mechanical Ventricular Actuation (B) in 30 Minute Acute Hearts.
Immunoblots were performed using 40ug of protein with anti-Caspase-9antibody to measure the relative
protein content as described in the Methods section. In (A), five acute hearts represented in lanes 1-5 had
heart failure induced for 30 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes. In (B), six acute hearts represented in lanes 6-11 heart failure induced while receiving direct
mechanical ventricular actuation support for 30 minutes and were normalized to GAPDH at a 1:5000
dilution for quantification purposes.
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Figure 40- Immunoblotting Representation of Caspase-9 Content in the Right Ventricle During
Heart Failure (A) and Direct Mechanical Ventricular Actuation (B) in 60 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase9antibody to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 60 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), seven extended
support/failure hearts represented in lanes 6-12 had heart failure induced while receiving direct mechanical
ventricular actuation support for 60 minutes and were normalized to GAPDH at a 1:5000 dilution for
quantification purposes.
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Figure 41- Immunoblotting Representation of Caspase-9 Content in the Right Ventricle During
Heart Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 40ug of protein with anti-Caspase9antibody to measure the relative protein content as described in the Methods section. In (A), five extended
support/failure hearts represented in lanes 1-5 had heart failure induced for 120 minutes and were
normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six extended support/failure
hearts represented in lanes 6-11 had heart failure induced while receiving direct mechanical ventricular
actuation support for 120 minutes and were normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 42- Relative Caspase-9 Content in the Right Ventricle in Acute (A) and Extended
Support/Failure (B) Hearts. Values as mean ± SEM of relative protein amount. In (A), data are
presented from six acute hearts for the direct mechanical ventricular actuation (DMVA) trial and sham trial,
and five acute hearts for the heart failure (HF) trial. In (B), data are presented from five extended
support/failure hearts for each HF trial, seven extended support/failure hearts for the 60 DMVA trial and
six extended support/failure hearts for the 120 DMVA trial.
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Cytochrome-C Immunoblotting
Cytochrome-C was used as a marker to measure cell viability. The levels should
have remained constant over all groups as long as there was no cell death occurring at a
greater than normal rate. Immunoblots of cytochrome-C content in the left ventricle
showed that there was a large amount of cytochrome-c present in all total cell extracts. In
the sham group the total content varied within the group, but the variance within the
group did not create an outlier. The amount of cytochrome-c did not change over the
duration of the experiment in either the heart failure or the DMVA groups (Fig 43-44).
These trials were only run once to determine quickly if there was any cell death
occurring, which would have been seen by a decrease in cytochrome-c protein content
per lane. The fact that no change was observed suggests that to a large extent cell death
had not occurred in either model.
Immunoblots of cytochrome-C content was also done in the right ventricular
extracts, again showing a large amount being present in total cell samples. The amount
of cytochrome-c did not change significantly over the duration of the experiment in either
the heart failure or the DMVA groups. Figures of the sham group and 120 minute groups
are shown (Fig 45-46). The 120 minute group had one outlier in the 120 minute heart
failure group (Fig. 46A, lane 5), other than that the relative densities between the heart
failure and the DMVA groups were no significantly different from each other or the sham
group. Our results suggest that there was little or no necrosis in the tissues during our
experimental procedure.
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Figure 43- Immunoblotting Representation of Cytochrome-C Content in the Left Ventricle of Sham
Acute Hearts. Immunoblots were performed using 25ug of protein with anti-Cytochrome-C antibody at a
dilution of 1:5000 to measure the relative protein content as described in the Methods section. Six sham
acute hearts are represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 44- Immunoblotting Representation of Cytochrome-C Content in the Left Ventricle During
Heart Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 25ug of protein with anti-Cytochrome-C
antibody at a dilution of 1:5000 to measure the relative protein content as described in the Methods section.
In (A), five extended support/failure hearts represented in lanes 1-5 had heart failure induced for 120
minutes and were normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six
extended support/failure hearts represented in lanes 6-11 had heart failure induced while receiving direct
mechanical ventricular actuation support for 120 minutes and were normalized to GAPDH at a 1:5000
dilution for quantification purposes.
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Figure 45- Immunoblotting Representation of Cytochrome-C Content in the Right Ventricle of Sham
Acute Hearts. Immunoblots were performed using 25ug of protein with anti-Cytochrome-C antibody at a
dilution of 1:5000 to measure the relative protein content as described in the Methods section. Six sham
acute hearts are represented in lanes 1-6, each normalized to GAPDH at a 1:5000 dilution for quantification
purposes.
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Figure 46- Immunoblotting Representation of Cytochrome-C Content in the Right Ventricle During
Heart Failure (A) and Direct Mechanical Ventricular Actuation (B) in 120 Minute Extended
Support/Failure Hearts. Immunoblots were performed using 25ug of protein with anti-Cytochrome-C
antibody at a dilution of 1:5000 to measure the relative protein content as described in the Methods section.
In (A), five extended support/failure hearts represented in lanes 1-5 had heart failure induced for 120
minutes and were normalized to GAPDH at a 1:5000 dilution for quantification purposes. In (B), six
extended support/failure hearts represented in lanes 6-11 had heart failure induced while receiving direct
mechanical ventricular actuation support for 120 minutes and were normalized to GAPDH at a 1:5000
dilution for quantification purposes.
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Superoxide Dismutase Enzyme Activity Assay
Superoxide ions (SOD) measure the buildup of chemical stress ions in cells. It
has also been suggested that SOD plays a role in helping to initiate apoptosis through the
extrinsic pathway. The enzymatic activity of SOD in the left ventricle increased at both
30 minute groups when compared to the sham group, although none of the increases were
considered significant ( having a p value less than or equal to 0.05). In the groups that
had DMVA assistance, there was little or no change in the SOD activity, with the
exception of an increase in the 30 minute DMVA group, which was not considered
significant. The differences between all groups became apparent once the duration
reached 60 minutes. SOD specific enzyme activity in the 60 minute heart failure group
was significantly higher than the 60 minute group with DMVA assistance (88% vs. 86%,
p=0.03) and the difference became larger at the 120 minute point (89% vs. 86%,
p<0.01). The difference between the 60 minute heart failure group and the 120 minute
DMVA group was also significant with a p value of 0.01 (Fig. 47). It can be concluded
that the use of DMVA attenuated the production of superoxide ions, suggesting that the
upregulation of SOD by heart failure was attenuated. In the left ventricle the use of
DMVA decreased the amount of chemical stress observed when compared to the group
exposed to only heart failure.
In the right ventricle the difference between the sham group and the 30 minute HF
group were considered significant. When individual groups where compared with each
other at each time point, a difference was observed at the 30 minute time point between
heart failure and DMVA (84% vs. 80%, p=0.03). There was no difference at 60 minutes
and only a slight increase in SOD activity in the heart failure group at 120 minutes.
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There was little difference seen between the 60 and 120 minute time points (Fig. 48).
The benefits of DMVA in the right ventricle were less pronounced than in the left
ventricle, with only an improvement exhibited at the 30 minute time point, but not within
the group at the 30 minute point. The rest of the time points showed no difference
between the normal rate of SOD expression in heart failure by itself or with DMVA
assistance. This trend throughout all the time point did show that DMVA was always
slightly lower in SOD than heart failure.
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Figure 47- Relative SOD Activity in the Left Ventricle in Acute (A) and Extended Support/Failure
(B) Hearts. Values as mean ± SEM of percent inhibition by SOD (%), and *P<0.03 60 vs. 60 HF and
†P<0.02 120 DMVA vs. 60 HF and P<0.003 120 DMVA vs. 120 HF. A SOD activity assay kit was used
to get the relative content as described in the Methods section. In (A), data are presented from six acute
hearts for the direct mechanical ventricular actuation (DMVA) trial and sham trial, and five acute hearts for
the heart failure (HF) trial. In (B), data are presented from five extended support/failure hearts for each HF
trial, seven extended support/failure hearts for the 60 DMVA trial and six extended support/failure hearts
for the 120 DMVA trial.
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Figure 48- Relative SOD Activity in the Right Ventricle in Acute (A) and Extended Support/Failure
(B) Hearts. Values as mean ± SEM of percent inhibition by SOD (%), and * P<0.0001 30 HF vs. Sham
and †P<0.03 30 DMVA vs. 30 HF. A SOD activity assay kit was used to get the relative content as
described in the Methods section. In (A), data are presented from six acute hearts for the direct mechanical
ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure (HF) trial. In
(B), data are presented from five extended support/failure hearts for each HF trial, seven extended
support/failure hearts for the 60 DMVA trial and six extended support/failure hearts for the 120 DMVA
trial.
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MMP-9 Enzyme Activity Assay
Matrix metalloprotease 9 (MMP-9) is an important marker for the overall
structure of cardiac tissue. The increase in MMP-9 activity was observed in hearts that
are breaking down the cellular matrix due to the enlarging of the heart. This occurs
because as the cells enlarge MMP-9 is released to breakdown the extra cellular matrix to
allow this growth of the cells to occur and the dilation of the ventricles ensues. In the left
ventricle, there was a significant increase in both 30 minute groups when compared to the
sham group, an increase of 118% (0.80 vs. 1.74, p=0.0001) in the 30 minute heart failure
group and an increase of 94% (0.80 vs. 1.55, p=0.003) in the 30 minute DMVA group
(Fig. 49). Within each time point there were no groups that showed any difference
between heart failure and DMVA. The effect of heart failure was only observed initially
in the 30 minute time point and after 30 minutes there was no change observed. This
suggested that there was no great increase in MMP-9 activity.
The right ventricle showed similar results as the left ventricle in that there was a
significant increase from the sham group to both 30 minute groups and then a slight
increase from 60 minutes to 120 minutes, but not within time points (Fig. 50). The
increase in MMP-9 enzyme activity showed that there was the general breakdown in the
matrix and overall structure of the heart being compromised due to the failure. It was
unusual to see no difference between heart failure and heart failure with DMVA
assistance, since the DMVA cup should be able to protect the heart from enlargement.
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Figure 49- Relative MMP-9 Activity in the Left Ventricle in Acute (A) and Extended Support/Failure
(B) Hearts. Values as mean ± SEM of arbitrary units, and * P<0.0001 30 HF vs. sham, †P<0.003 30
DMVA vs. sham. A MMP-9 activity assay kit was used to get the relative content as described in the
Methods section. In (A), data are presented from six acute hearts for the direct mechanical ventricular
actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure (HF) trial. In (B), data are
presented from five extended support/failure hearts for each HF trial, seven extended support/failure hearts
for the 60 DMVA trial and six extended support/failure hearts for the 120 DMVA trial.
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Figure 50- Relative MMP-9 Activity in the Right Ventricle in Acute (A) and Extended
Support/Failure (B) Hearts. Values as mean ± SEM of arbitrary units, and * P<0.002 30 DMVA vs.
sham and †P<0.002 30 HF vs. sham. A MMP-9 activity assay kit was used to get the relative content as
described in the Methods section. In (A), data are presented from six acute hearts for the direct mechanical
ventricular actuation (DMVA) trial and sham trial, and five acute hearts for the heart failure (HF) trial. In
(B), data are presented from five extended support/failure hearts for each HF trial, seven extended
support/failure hearts for the 60 DMVA trial and six extended support/failure hearts for the 120 DMVA
trial.
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MMP-9 Zymography
This test for MMP-9 was meant to see the overall expression of MMP-9; however
the method was less sensitive than the enzymatic assay. Multiple trials using various
load amounts, tissue preparation protocols, and incubation periods were run on a
zymogram gel (data not shown) to determine if there was a significant amount of MMP-9
present. All trials produced the same result of either no MMP-9 protein present or as the
load became higher only excess protein was present with no increase in MMP-9. These
tests were done using both left ventricle and right ventricle homogenates.
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Discussion
The results of the study demonstrate significant findings that support the study
hypothesis that DMVA can improve ventricular pump function of the failing rabbit heart
while attenuating maladaptive cell signaling that characterizes heart failure. Multiple
markers of heart failure were looked at to build an overall picture of how heart failure
was progressing with and without DMVA assistance. The data showed that DMVA
assistance was able to improve the heart’s ability to attenuate the molecular signaling
involved in pro-apoptotic signaling and markers associated with mechanical stretch. A
table of these results (Table 1) summarizes the types of markers that were examined and
the trends seen in this study. The hearts were also split into an acute model and an
extended support/failure model to account for the duration of heart failure used as the
control and 30 minute time points and the extended durations of the 60 minute and 120
minute time points. Intrinsic and extrinsic early signaling pathways of apoptosis were
looked at to analyze how pro-apoptotic events were initializing. Mechanical and
oxidative stress markers were used to evaluate how the structure of the heart was being
affected during heart failure. Lastly both pathways could be linked together to better
understand how they interacted to induce heart failure and what affects using DMVA had
on that system (Fig. 51).
The model used in this study proved to be a valid one for testing the effects of
heart failure. It clearly demonstrated the upregulation of multiple markers associated
with heart failure, to be discussed later. This was an important finding to verify the
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Table 1- Summary of results for the left and right ventricles in both the Acute and Extended
support/failure models for heart failure. The general conclusions from each marker tested are
summarized to give a quick overview of all the results obtained in this study.

139

Acute
LV

RV

Extended
support/failure
LV
RV

Extrinsic
Pathway

TNFR

Significant
increase in
both
groups

Slight
increase in
both groups

Caspase-8:
Immunoblotting

Slight
increase at
30 minutes
for both
groups

Not
performed
(antibody
was
discontinued)

Caspase-8:
Enzymatic Assay

Decrease
in both
groups
from sham.
Significant
difference
at 30
minutes

Slight
decrease in
30 DMVA
versus 30 HF

Caspase-9

No
differences

No
differences

Cytochrome-C

No
differences

No
differences

DMVA
attenuated
the
activation of
TNFR at
120 minutes
DMVA
attenuated
the
activation of
Caspase-8
at 120
minutes
DMVA
attenuated
the
activation of
Caspase-8
at 120
minutes

Significant
increase in
both groups,
slight
attenuation in
120 DMVA

Not performed
(antibody was
discontinued)

DMVA
attenuated the
activation of
Caspase-8 at
120 minutes

Intrinsic
Pathway
Significant
increase in
both groups
No
differences

Slight increase
in both groups
No differences

Stress Markers

Hsp70

Significant
increase in
both
groups

No
differences

DMVA
attenuated
the
activation of
Hsp70 at
both 60 and
120 minutes

MMP-9:
Enzymatic Assay

Significant
increase in
both
groups

Significant
increase in
both groups

No
differences

Slight increase
in both groups

SOD

Slight
increase in
both
groups

Significant
increase in
the 30 HF

DMVA
attenuated
SOD at both
60 and 120
minutes

No differences
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Significant
increase in
both groups

Figure 51- The Apoptotic Pathway. An overall diagram to show the proposed pathways looked at in this
study. It shows a collaboration of multiple apoptotic diagrams to illustrate how the markers in this study
can be related to each other.
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validity of the model and its use in future studies. The model was ideal due to its
relatively easy administration and the ability to monitor and alter the dosing rates of the
drugs made it possible to adjust the severity of failure to make it consistent from one trial
to the next.

Extrinsic Pathway of Apoptosis
For the extrinsic pathway (Fig. 3), we first determined the tumor necrosis factor receptor
(TNFR) content in the heart extracts to determine if more TNF-alpha was being recruited
to initiate the caspase cascade. The overall trend in the data suggested that in both
ventricles there was a steady increase in the concentration of activated receptors. In the
acute model increases were observed at 30 minutes in both ventricles. The left ventricle
saw a slight trend that DMVA was attenuating the rise in TNFR at 30 minutes. The
extended support/failure model showed an increase in TNFR content from the 60 minute
time point into the 120 minute time point, further exhibiting the signs of pro-apoptotic
signaling in this model of heart failure. The use of DMVA assistance attenuated the rise
in TNFR activation in the 60 and 120 minute time point in the left ventricle. In the left
ventricle, the DMVA device was able to attenuate significantly the amount of TNFR that
was being activated; an indication that heart failure with DMVA support attenuated the
signaling for pro-apoptotic events that occur through TNFR. The right ventricle showed
similar trends as in the left ventricle, however, there were no significant differences
between the heart failure and the DMVA assisted groups at any time point. The possible
reason for the right ventricle not exhibiting an impediment of TNFR activation is not
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completely known, but some theories as to why the left ventricle and the right ventricle
reacted differently will be discussed later.
We next tested at an apoptotic marker that the TNFR is directly linked to,
caspase-8. We used immunoblotting to show all the forms of caspase-8 in the extracts
and an enzymatic assay to examine the amount of activated caspase-8 present in the
differently treated hearts. The immunoblotting evidence was limited to the left ventricle
due to the discontinuation of the antibody being used. Our results showed little
difference in the activation of caspase-8 in the acute left ventricle. There was a rise in
both 30 minute groups when compared to the sham group. However, the extended
support/failure model did provide evidence that in the 120 minute heart failure group
there was an 88.5% increase when compared to the 60 minute heart failure group. This
was additional evidence that the use of DMVA was able to attenuate progression along
the extrinsic pathway by limiting the activation of caspase-8.
Since the immunoblots only determined caspase-8 in the left ventricle we used an
enzymatic assay for caspase-8 to correlate with immunoblotting results and to in addition
examine caspase-8 in the right ventricle. In the left ventricle we further confirmed the
results from the immunoblots. There was evidence that the left ventricle with DMVA
assistance exhibited attenuation of pro-apoptotic signaling by the activation of caspase-8.
In the right ventricle there were no changes in caspase-8 activity in the acute groups
when compared to each other or the sham group. However, the extended support/failure
hearts showed both 120 minute groups having an increase in caspase-8 activation, with
the 120 minute DMVA group showing a significant increase from the 60 minute heart
failure. The average values for 120 HF were actually greater that 120 DMVA for
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caspase-8, but the range for 120 HF were also greater. The fact that there is no difference
in the activation levels of caspase-8 between heart failure and DMVA assistance is of
interest in the right ventricle since the left ventricle is seeing a significant difference.
One possible explanation is that the right ventricle is less capable of withstanding the
force created by the DMVA cup during contraction and therefore is less likely to benefit
from the actions of DMVA.

Intrinsic Pathway of Apoptosis
Caspase-9 was a main focus of how the intrinsic pathway was affected in this
model (Fig. 2). We were uncertain whether we would see changes in caspase-9 due to
the idea that the intrinsic pathway is more related to chemical stress and DNA damage
(Crow, 2004), which was not expected to be present in this model or these shorter
durations. The acute model saw no change in caspase-9 in either the left or the right
ventricle. The extended support/failure model did show signs of increased activation
over time, but no changes were observed between heart failure and DMVA in either the
left or the right ventricle (Appendix A). The left ventricle had a significant increase in
both 120 minute groups compared to the 60 minute heart failure. The right ventricle
showed similar trends, but not to a significant level. The results showed that caspase-9
and the intrinsic pathway were neither attenuated nor aggravated by DMVA assistance in
heart failure. Our results, although limited, suggest that DMVA did not have any effect
on the intrinsic pathway through caspase-9.
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Stress Markers of Heart Failure
There are two different stress related markers for heart failure that we examined.
The first was based on mechanical stress markers which are initiated by the stretching of
the myocardial cells and the overloading of the ventricles. Heat shock protein 70
(Hsp70) is a common protein that is activated in response to the stretching of the
myocardium to help preserve the native structure of proteins being damaged. In the acute
left ventricle, there was little effect of DMVA on Hsp70 at the 30 minute time point.
During heart failure, there was a significant increase in the amount of activated Hsp70
measured in both the left and the right ventricles of the extended support/failure. At 60
minutes and carrying into 120 minute experimental duration, DMVA assistance
attenuated the amount of Hsp70 that was being recruited. The left ventricle saw a
significant difference between heart failure and DMVA at 120 minutes. At that same
time point the right ventricle had a similar trend, but not significant. This could be
related to the DMVA device’s ability to limit the amount of left ventricle overloading that
can be responsible for much of the myocardial stretch during heart failure (Fedak, Part I,
2005). Since it has been shown that stretch alone can lead to Hsp70 recruitment, we can
theorize that DMVA limited the amount of mechanical stretch placed on the left ventricle
(Knowlton, 1991).
In the right ventricle, DMVA assistance during heart failure did not attenuate
Hsp70 recruitment as well as the left ventricle. Both groups showed similar increases in
the amount of Hsp70 being recruited over time. The use of DMVA assistance did not
attenuate that level significantly at any time point. One possible reason behind this could
be that the right ventricle is much thinner and therefore, it has weaker contractility as
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compared to the left ventricle. The cells in the right ventricle stretched more readily and
even with some support the tissue was being damaged, as indicated by increased Hsp70
content. Another possible cause could be in the action of the cup itself on the heart tissue
in the right ventricle. Since the heart rate of a rabbit is high to begin with, the cup was
contracting and expanding at a relatively fast rate. While the heart function may have
been kept normal from a mechanical sense, the actual force of the cup on the right
ventricle might have been too much and thus causing some damage of its own. In a few
echocardiograph images made during our experiments, we observed that the DMVA cup
could at times over compress the ventricles. In contrast, the left ventricle is a much
stronger muscle and was physically more capable of handling this over compression.
Matrix metalloproteinase 9 (MMP-9) is another marker that is commonly used in
heart failure to asses mechanical stress from ventricle overloading (Fedak, Part II, 2005).
Unlike Hsp70, which reacts in response to cellular events, MMP-9 is found in the
interstitial and is recruited when the extracellular matrix is being broken down. We used
zymography to assess the levels of MMP-9 in the ventricles. Our results were unable to
measure any MMP-9 using the zymograms. A previous study done by Dr. Anstadt also
used zymography and did find significant differences of MMP-9 levels between heart
failure and DMVA assistance. Due to those previous findings and our inability to get
results from zymography we used an enzymatic assay to evaluate MMP-9. We observed
an increase in MMP-9 relatively from the sham group compared to the acute samples at
30 minutes in both the left and right ventricles. Extended support/failure extracts from
both ventricles did not show an increase of MMP-9 content over time of heart failure or
between groups. The initial increase observed (Appendix A) did not continue with
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increasing experiment times possibly due to an initial overload of MMP-9 in the system
and no further recruitment. We expected to see the rise in MMP-9 levels, but there was
no attenuation like seen in the previous study.
Superoxide dismutase (SOD) was observed to determine if there was an increase
in harmful free radicals created during the heart failure process. The most widely used
model for heart failure relies on ischemia/reperfusion, which restricts blood flow to the
heart and causes a shortage of oxygen. During reperfusion the blood flow is restored, but
the sudden reintroduction of oxygen causes the production of free radicals. Our model
hoped to eliminate those confounding effects cause by ischemia, monitored in this case
by SOD. Increases in SOD were thus expected to be caused from the stretch occurring
from heart failure and the ventricular overloading. The enzymatic assay that was run
showed that the SOD levels in the left ventricle were increased significantly as the
duration of heart failure increased. There was a difference in the heart failure groups
compared to the DMVA assisted groups at the 60 minute and 120 minute time points,
where DMVA significantly attenuated the production of SOD. This trend showed that
while heart failure induced a steady increase in the amount of SOD, the use of DMVA
showed an attenuation of the amount of SOD present.
In the right ventricle there was a significant increase in SOD activity of the 30
minute heart failure compared to both the sham and 30 minute DMVA groups. At the
other time points, there were no differences between heart failure and heart failure with
DMVA assistance. At 120 minutes there was a slight attenuation of SOD in the DMVA
group. The trend in the right ventricle shows some promise that at 120 minutes the levels
of SOD appear to be rising in the heart failure group, but DMVA shows no similar rise
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when compared to 60 minutes. These results in both ventricles lead to the conclusion that
the use of DMVA assistance was attenuating the rise in SOD, likely due to the stretch
occurring in the ventricles during heart failure. A rise in the free radicals would be a
possible precursor for future cell damage, leading to cell death.
This study showed many positive trends as far as DMVA’s ability to retard the
onset of various markers of heart failure. At points these differences were significant, but
just as importantly there was a consistent pattern of some benefit of using the DMVA
device during heart failure. There were a few examples where at 120 minutes the
differences were not significant, but were showing trends towards DMVA attenuation of
pro-apoptotic markers. It is important to note that this model is for an acute heart failure,
where it may be less likely to see many significant changes in the short time period used.
The benefits shown by this study prove that is prudent to look further into the benefits
this device would have on a chronic heart failure model at longer time periods.
There were some limitations to this study. The use of immunoblots creates a
good picture of the protein content in each different pathway, but in general, the results
are limited by having an error of around 10% when quantitated. Multiple trials were used
to limit this error. The use of enzyme assays was able to confirm the effectiveness of the
immunoblots in the case of caspase-8, helping to provide stronger evidence that the use
of immunoblotting was valid. The pathways examined were routine markers commonly
examined in other studies analyzing the effects of heart failure: future studies should
focus more on each pathway and the additional markers that play a role in apoptosis
during heart failure. One final limitation was in the use of the rabbit heart itself. While it
is a commonly used model, the high heart rate could have a negative affect when using
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the DMVA cup. The problem is that the high rate of compression with the cup itself
could be a problem by creating additional trauma to the failing heart. However, if that
were the case, then DMVA assistance would have exhibited more negative effects in the
results from the markers being studied. Our results showed that this was not the case and
the data presented here provides a good sign for human trials in which the heart rate is
slower.

Concluding Remarks
Our results give a general view of how apoptosis and stress damage propagate
during heart failure, with and without DMVA assistance. The findings provided some
positive results for the use of DMVA assistance to attenuate the negative cellular
responses that occur during heart failure. It was a positive sign that there were no
negative effects on the heart tissues from the use of DMVA assistance. Furthermore,
there were many positive results that as the duration of heart failure increased, the
markers of apoptosis and cellular stress were either unaffected or they were attenuated.
Although more tests are required to confirm these results, it was shown by our study that
the use of DMVA assistance may attenuate the degradation of heart tissue by proapoptotic signaling and cellular stress during heart failure.
Another finding from this study concerns the model of heart failure being used.
Before the results could be used it had to be determined that we were inducing a heart
failure state by causing ventricular overloading with esmolol. There was a consistent
increase in the levels of the markers being looked at for heart failure that provided the
best evidence that heart failure was occurring as duration increased. Those increases in
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the markers for heart failure showed strong evidence that we were able to induce heart
failure by using esmolol to cause ventricular overloading and enlargement of the heart.
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Append ix A
Left Ventricle Acute Heart Failure
Sham

30 HF

30 DMVA

Mean ± SEM

Mean ± SEM

Mean ± SEM

0.193 ± 0.006

0.340 ± 0.026*

0.308 ± 0.016**

0.572 ± 0.085

0.750 ± 0.065

0.753 ± 0.089

0.0052 ± 0.0006

0.0045 ± 0.0002***

0.0032 ± 0.0005†

Caspase-9

0.060 ± 0.011

0.064 ± 0.006

0.085 ± 0.019

Cytochrome-C

-

-

-

Hsp-70

0.058 ± 0.012

0.152 ± 0.017††

0.145 ± 0.021‡

SOD (%)

84.9 ± 1.67

87.9 ± 0.73

87.8 ± 0.27

MMP-9

0.797 ± 0.079

1.741 ± 0.145‡‡

1.546 ± 0.208#

Extrinsic
Pathway
TNFR
Caspase-8
(Immunoblotting)
Caspase-8
(nmols/min/mg)
Intrinsic
Pathway

Stress Markers

*P<0.0002 30 HF vs. Sham
**P<0.0001 30 DMVA vs. Sham
***P<0.03 30 HF vs. 30 DMVA
†P<0.02 30 DMVA vs. Sham
††P<0.001 30 HF vs. Sham
‡P<0.005 30 DMVA vs. Sham
‡‡P<0.0001 30 HF vs. Sham
#P<0.003 30 DMVA vs. Sham
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Left Ventricle Extended/Support Heart Failure
60 HF

60 DMVA

120 HF

120 DMVA

Mean ± SEM

Mean ± SEM

Mean ± SEM

Mean ± SEM

0.460 ± 0.040

0.631 ± 0.086

1.738 ± 0.084*

1.292 ± 0.127**†

0.518 ± 0.042

0.556 ± 0.057

0.988 ± 0.076***

0.567 ± 0.119†

0.0047 ± 0.0007

0.0058 ± 0.0004

0.0080 ± 0.0098††

0.0055 ± 0.0003‡

Caspase-9

0.092 ± 0.015

0.094 ± 0.013

0.158 ± 0.014††

0.148 ± 0.013‡‡

Cytochrome-C

-

-

-

-

Hsp-70

0.518 ± 0.066

0.315 ± 0.041#

1.536 ± 0.191##

1.048 ± 0.088∞∆

SOD (%)

88.1 ± 0.61

85.8 ± 0.66∞∞

88.9 ± 0.70

85.5 ± 0.70‡‡∆∆

MMP-9

1.776 ± 0.170

1.812 ± 0.132

1.956 ± 0.284

2.160 ± 0.170

Extrinsic
Pathway
TNFR
Caspase-8
(Immunoblotting)
Caspase-8
(nmols/min/mg)
Intrinsic
Pathway

Stress Markers

*P<0.0001 120 HF vs. 60 HF
**P<0.0003 120 DMVA vs. 60 HF
†P<0.02 120 DMVA vs. 120 HF
***P<0.0006 120 HF vs. 60 HF
†P<0.02 120 DMVA vs. 120 HF
††P<0.01 120 HF vs. 60 HF
‡P<0.008 120 DMVA vs. 120 HF
‡‡P<0.02 120 DMVA vs. 60 HF
#P<0.02 60 DMVA vs. 60 HF
##P<0.001 120 HF vs. 60 HF
∞P<0.04 120 DMVA vs. 120 HF
∆P<0.001 120 DMVA vs. 60 HF
∞∞P<0.03 60 DMVA vs. 60 HF
∆∆P<0.003 120 DMVA vs. 120 HF
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Right Ventricle Acute Heart Failure
Sham

30 HF

30 DMVA

Mean ± SEM

Mean ± SEM

Mean ± SEM

0.148 ± 0.001

0.246 ± 0.034*

0.218 ± 0.025**

-

-

-

0.0049 ± 0.0004

0.0052 ± 0.0005

0.0038 ± 0.0007

Caspase-9

0.095 ± 0.015

0.086 ± 0.010

0.108 ± 0.016

Cytochrome-C

-

-

-

Hsp-70

0.080 ± 0.008

0.090 ± 0.023

0.0583 ± 0.0202

SOD (%)

79.1 ± 0.57

83.9 ± 0.62***

80.4 ± 1.28†

MMP-9

0.899 ± 0.0515

1.389 ± 0.105††

1.276 ± 0.091‡

Extrinsic Pathway
TNFR
Caspase-8
(Immunoblotting)
Caspase-8
(nmols/min/mg)
Intrinsic Pathway

Stress Markers

*P<0.02 30 HF vs. Sham
**P<0.03 30 DMVA vs. Sham
***P<0.0001 30 HF vs. Sham
†P<0.03 30 DMVA vs. 30 HF
††P<0.0003 30 HF vs. Sham
‡P<0.002 30 DMVA vs. Sham

154

Right Ventricle Extended/Support Heart Failure
60 HF

60 DMVA

120 HF

120 DMVA

Mean ± SEM

Mean ± SEM

Mean ± SEM

Mean ± SEM

0.302 ± 0.043

0.364 ± 0.026

0.552 ± 0.056*

0.457 ± 0.028**

-

-

-

-

0.0039 ± 0.0004

0.0033 ± 0.0002

0.0059 ± 0.0010

0.0048 ± 0.0002***

Caspase-9

0.064 ± 0.021

0.054 ± 0.010

0.112 ± 0.013

0.105 ± 0.008

Cytochrome-C

-

-

-

-

Hsp-70

0.172 ± 0.016

0.191 ± 0.027

0.376 ± 0.038†

0.337 ± 0.0520††

SOD (%)

84.4 ± 1.01

84.3 ± 1.20

86.3 ± 1.46

84.2 ± 0.98

MMP-9

1.488 ± 0.148

1.488 ± 0.103

1.704 ± 0.157

1.652 ± 0.156

Extrinsic
Pathway
TNFR
Caspase-8
(Immunoblotting)
Caspase-8
(nmols/min/mg)
Intrinsic
Pathway

Stress Markers

*P<0.01 120 HF vs. 60 HF
**P<0.01 120 DMVA vs. 60 HF
***P<0.03 120 DMVA vs. 60 HF
†P<0.001 120 HF vs. 60 HF
††P<0.02 120 DMVA vs. 60 HF
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